Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Stock-plunging mRNA vaccine maker, already in bed with feds on vaccine royalties, says booster not "causally" related without ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Moderna slashed its 2025 revenue projection by $1bn on Monday, citing reduced demand for its Covid-19 and respiratory ...

Moderna submitted data to the Food and Drug ... The side effects from the booster shots appear to be similar to those from the original series in this age group as well as in adults, Dr. Steven ...

while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs. "The bumpy ride gets bumpier," said Bernstein analyst Courtney Breen ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...

(Reuters) - Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines. It expects $1.5 ...

In July 2024, Moderna was awarded $176 million from the US government to advance the development of its mRNA H5N1 (bird flu) vaccine, which is in the early stages of testing. The award came after ...